Access and Advocacy: “Share the Savings”

Mainstage at the GA Life Sciences Summit

Americans want policymakers to see lowering out-of-pocket costs for health care as a top priority. Putting pharma and its innovators who invest billions of dollars in R&D for therapies that improve outcomes and save lives in villainous crosshairs is easy to understand and politically expedient, but misguided.

In 2021, West Virginia became the first state in the nation to adopt ground-breaking legislation, HB2263, requiring insurers and their PBMs to share the savings they negotiate on medicines directly with patients. This legislation serves as a roadmap for other states looking to help lower costs for patients. In the upcoming Georgia legislative session, the state joins that effort with HB 343, most specifically “to require pharmacy benefits managers to calculate defined cost sharing for insureds at the point 4 of sale.”

“People are familiar with the ‘negotiated rate’ they see on a bill from their doctor for a procedure or visit,” Zachary Poss, Director of State Advocacy for PhRMA said. “That reflects a discount compared to published or uninsured rates for those services and procedures. Rebates or discounts pharma provides don’t make their way to patients the way discounts reflected in negotiated rates between insurers, providers and patients do. Those rebates for drugs are held by pharmacy benefits managers. They do not make their way to the patients as they should.”

Making HB 343 law in the State of Georgia would be a strong way to change that.

Dorothy Leone-Glasser (RN, HHC), Executive Director of Advocates for Responsible care encouraged all to, “Become more engaged. What you create saves lives. Pay attention to the legislative alerts. Write an op ed. Support this legislation.”

Mainstage at the GA Life Sciences Summit
September 11, 2025
Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.
By Maria Thacker Goethe September 5, 2025
Protecting U.S. Leadership in Agricultural Biotechnology
By Maria Thacker Goethe August 29, 2025
Celebrating the Next Generation of Scientific Breakthroughs in Georgia
MORE POSTS